Dec 20 (Reuters) - Aeterna Zentaris Inc:
* Receives agreement from FDA on special protocol assessment for Solorel
(AEZS-130, macimorelin) to complete registration study for diagnosis of adult
growth hormone deficiency
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Receives agreement from FDA on special protocol assessment for Solorel
(AEZS-130, macimorelin) to complete registration study for diagnosis of adult
growth hormone deficiency
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2010 AFX News
